Resistance to drug treatments underlies the high lethality of pancreatic ductal adenocarcinoma. Along with others, we have recently identified that proteasome inhibition is a promising therapeutic option in this highly refractory disease. The pleiotropic effects of proteasome inhibition include the activation of apoptotic signaling pathways and also antiapoptotic signaling pathways such as EGFR, AKT and the MAP kinases that reduce the apoptotic potential of this class of drug. In this study, we sought to determine the mechanism behind the activation of EGFR in response to proteasome inhibition in pancreatic cancer cells. We found that the second-generation proteasome inhibitor NPI-0052 induced the mRNA transcription of several EGFR family ligands (EGF, HB-EGF and epiregulin), however only increases in HB-EGF were detected at the protein level. Using both pharmacological inhibitors and lentiviral-mediated shRNA knockdown of EGFR ligand expression, we discovered that ligand cleavage by MMP/ADAMs and HB-EGF expression is required for activation of EGFR in response to proteasome inhibition. Furthermore, we discover that induction of HB-EGF is dependent on reactive oxygen species and p38-MAPK signaling but not ERK and that the transcription factor SP-1 is involved in NPI-0052-induced HB-EGF transcription. Together, these results indicate that stress signaling leading to induction of HB-EGF expression and increases in MMP/ADAM-dependent HB-EGF cleavage are responsible for proteasome inhibitor-induced activation of EGFR in pancreatic cancer cells.
Introduction
Pancreatic ductal adenocarcinoma (PDA) has a 5-year survival rate of less than 5% (Jemal et al., 2008) . To date, chemo-and radiotherapy regimens have failed to increase patient survival times significantly. Resistance to chemotherapy and molecularly targeted therapies is thought to underlie these treatment failures (Giovannetti et al., 2006) . Recent work from our group has identified HB-EGF as having a key role in PDA chemoresistance (Wang et al., 2007a, b) . HB-EGF binds to EGFR and HER4 leading to activation of several signal transduction cascades that have critical function in diverse cell fates including development, proliferation, differentiation and migration (Nishi and Klagsbrun, 2004) . HB-EGF expression has been implicated in tumor initiation and progression and it is overexpressed in many tumors including pancreatic, hepatocellular, colonic and bladder cancers (Raab and Klagsbrun, 1997) . Studies both in vitro and in human tumor specimens have additionally identified involvement of HB-EGF in resistance to a wide variety of clinically used molecular and genotoxic agents (Suganuma et al., 2003; Wang et al., 2007a) . These findings show that HB-EGF is not only a potent inducer of tumor growth but is also a survival factor involved in response to cellular stress.
Along with others, we have shown that proteasome inhibitors have broad in vitro and in vivo antitumor activity and can overcome chemoresistance in a number of cancer models including PDA (Milano et al., 2007; McConkey and Zhu, 2008) . This activity has been predominantly attributed to their ability to inhibit NF-kB, dysregulate the cell cycle, induce ER stress and stabilize proapoptotic proteins (Milano et al., 2007; McConkey and Zhu, 2008) . Despite being significantly more effective than standard chemotherapies at inducing apoptosis in pancreatic cancer cells, the pleiotropic effects of proteasome inhibition have also been shown to include the induction of several antiapoptotic mechanisms in various cell types. These include downregulation of proapoptotic JNK activity through induction of MAP kinase phosphatase-1 (Shi et al., 2006) ; decreased caspase-8 activation through cFLIP induction (Liu et al., 2007) and increased heat shock protein expression (McConkey and Zhu, 2008) . Likewise, we have recently shown that proteasome inhibition is able to increase EGFR, ERK, AKT and JNK signaling in pancreatic cancer cell lines and that these signals are predominantly antiapoptotic (Sloss et al., 2008) .
Results and discussion
In this study we sought to determine the biochemistry behind EGFR activation in response to proteasome inhibition. We first confirmed that treatment with the second-generation proteasome inhibitor NPI-0052 resulted in EGFR activation using various PDA cell lines: BxPC3, Capan2 and Panc1. These cell lines account for the various genetic lesions found in PDA including KRas activation and/or loss of one or more of the tumor suppressors p53, p16
INK4A and SMAD4. NPI-0052 treatment resulted in a time-dependent activation of EGFR, as measured by detection of tyrosine-1173 phosphorylation using immunoblotting analysis (Figure 1a) . Several other phosphotyrosine residues responsible for downstream EGFR signaling (Y1068 and Y1086) were also phosphorylated in response to NPI-0052 treatment (Figure 1a ) and the activation of BxPC3, Panc1, Capan2 were obtained from the ATCC (Rockville, MD, USA). Capan2 and Panc1 cells were grown in Dulbecco's modified Eagle's medium (DMEM); BxPC3 in RPMI. Media were supplemented with 10% fetal bovine serum and 100 mg/ml penicillin and streptomycin. (a) BxPc3, Panc1 and Capan2 cells were treated with 100 nM NPI-0052 (Nereus Pharmaceticals, San Diego, CA, USA) for the indicated times or (b) with the indicated concentrations of NPI-0052 for 4 h. Whole-cell extracts were prepared in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% s.d., 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM Na 3 VO 4 , 50 mM b-glycerophosphate, 1 mM PMSF) and immunoblotted for the indicated pTyr-residues on EGFR or the total form of EGFR. (c) BxPc3 cells were treated with 100 nM NPI-0052 for the indicated times. Total RNA was isolated using the RNeasy mini kit (Qiagen, Valencia, CA, USA) and 250 ng of RNA was used to measure the relative expression of EGFR ligands by RT-qPCR analysis using the indicated hydrolysis probes purchased from Applied Biosystems (Foster City, CA, USA) in 50 ml reactions performed using One Step qRT-PCR (Invitrogen, Carlsbad, CA, USA) on an ABI7300 system. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as control. Error bars represent standard error of the mean (s.e.m.) of at least three separate experiments, *Po0.05 by one-way analysis of variance (ANOVA) with Dunnet's post-test relative to untreated cells. (d) BxPc3 cells were treated with 100 nM NPI-0052 for the indicated times and expression of the indicated proteins was measured by immunoblotting.
EGFR by NPI-0052 was also dose dependent ( Figure 1b) . We similarly determined whether other HER family members were also activated and found that NPI-0052 treatment did not activate either HER2 or HER3 and that HER4 expression was not detectable in any of the cell lines tested (data not shown). The proteasome activity of all three cell lines showed low nano-or picomolar sensitivity to NPI-0052 treatment, which correlated with the cells sensitivity to NPI-0052-induced death (Supplementary Figure 1) . Increases in proteasome inhibitor-induced EGFR activation have been reported in squamous cell carcinoma (Lorch et al., 2007) , whereas in breast cancer cell lines bortezomib treatment reduced the activity of EGFR (CodonyServat et al., 2006) . These studies suggest that the response of EGFR to proteasome inhibition is cell-type specific.
Overexpression of many of the HER family ligands including EGF, HB-EGF, amphiregulin and epiregulin has been shown to be involved in pancreatic cancer cell growth, metastasis and to correlate with poor prognosis (Zhu et al., 2000; Hansel et al., 2003; Wang et al., 2007b) . We proceeded to analyze the expression of five EGFR ligands in response to proteasome inhibitor treatment. RT-qPCR analysis showed a time-dependent increase in the mRNA level of EGF, HB-EGF and epiregulin with significant increases at 4, 8 and 24 h after treatment. There was no significant change in the expression of amphiregulin or transforming growth factor-a ( Figure 1c ). Cellular HB-EGF protein levels were maximal after 8 h NPI-0052 treatment, which corresponded to the peak in EGFR activation ( Figure 1d ). Interestingly the EGF protein levels did not correlate with the activation of EGFR (Figure 1d ) nor the increase in EGF mRNA ( Figure 1c ). Epiregulin protein was undetectable by immunoblotting in treated or untreated cells (data not shown). To determine if the mRNA increases were a result of mRNA stabilization or the induction of de novo gene expression, we used the transcriptional inhibitor actinomycin-D. Actinomycin-D prevented NPI-0052-induced increases in both EGF and HB-EGF mRNA (Figure 2a ) and abrogated the increase of HB-EGF protein (Figure 2b) indicating the response is a transcriptional event. As HB-EGF functions both as a juxtacrine, membrane-bound protein and as an extracellular ligand, we used enzyme-linked immunosorbent assay to determine the levels of both cellular HB-EGF and the cleaved s-HB-EGF. NPI-0052 , growth media and wholecell extracts were analyzed for levels of HB-EGF expression by enzyme-linked immunosorbent assay (ELISA) using antibodies purchased from R&D Systems (Minneapolis, MN, USA). Samples were precleared by centrifugation at 5000 g for 5 min at 4 1C and 100 ml per well used for analysis as described in the manufacturer's protocol and as described previously (Wang et al., 2007a) . A standard curve was generated using rh-HB-EGF (R&D Systems) and used to quantify unknowns. Error bars represent s.e.m. of at least three separate experiments. *Po0.05 by Student's t-test. treatment significantly increased both cellular and cleaved s-HB-EGF levels ( Figure 2c) . Neutralizing antibodies were then used to sequester shed ligands from the media and as shown in Figure 2d , anti-HB-EGF, but not anti-EGF or anti-EREG, antibodies were able to reduce NPI-0052-induced EGFR activation. Antibody controls showing abrogation of ligand-induced EGFR activation by all three neutralizing antibodies are shown in Supplementary Figure 2b . Interestingly, the increases in HB-EGF shedding into the media were similar to the results previously reported for increases in HB-EGF shedding in response to the chemotherapy treatments SN-38 and doxorubicin (Wang et al., 2007a) . It remains to be determined if a common stress response mechanism underlies these similar findings. All EGFR ligands are cleaved at the cell surface by MMP/ADAMs to release the active ligand. To confirm if ectodomain shedding was involved in the activation of EGFR by proteasome inhibition, we treated pancreatic cancer cells with NPI-0052 in the presence of the broadspectrum MMP/ADAM inhibitor GM6001. GM6001 was able to prevent NPI-0052-induced activation of EGFR in a dose-dependent manner ( Figure 3a) and prevent cleavage and release of s-HB-EGF into the media (Supplementary Figure 2c) . Crm-197 (a potent and specific inhibitor of human HB-EGF) also completely abrogated the activation of EGFR by NPI-0052 (Figure 3b ).
Together these data suggest that HB-EGF expression and cleavage are responsible for proteasome inhibitorinduced EGFR activation. Similar data from other groups have implicated HB-EGF and its cleavage by MMP/ADAMs in the activation of EGFR in response to several types of stimuli including growth factors (Reznik et al., 2008) , GPCR activation (Miyamoto et al., 2006) and cellular stresses including chemotherapeutics and inflammatory cytokines (Takenobu et al., 2003; Wang et al., 2007a) . We additionally assessed if the lack of NPI-0052-induced EGFR activity in the breast cancer cell line SKBR3 (data not shown; CodonyServat et al., 2006) was due to a lack of HB-EGF induction. When treated with NPI-0052 both BxPc3 and SKBR3 cells showed marked increases in HB-EGF mRNA levels (Supplementary Figure 3a) whereas only BxPc3 cells had detectable HB-EGF protein expression (Supplementary Figure 3b) . This would suggest that the absence of proteasome-induced EGFR activity in SKBR3 cells is due to a lack of HB-EGF protein translation. A recent study has shed light on a possible explanation for this discordance between transcription and translation in response to proteasome inhibition. Zhu et al. (2009) have shown the phosphorylation state of eIF2a and disruption of polysome complexes can account for transcriptional independent suppression of protein translation in response to proteasome inhibitors. The authors suggest that proteasome inhibitors can specifically suppress translation of some proteins more than others and that the abundance of proteins, which are degraded by non-proteasome-dependent means, will be decreased in response to proteasome inhibitor treatment.
To confirm that HB-EGF is required for the activation of EGFR in response to NPI-0052, we engineered stable clones of BxPc3 cells lacking HB-EGF (Bx-shHB), EGF (Bx-shEGF) or epiregulin (Bx-shEREG) using lentiviral-mediated shRNA transduction. Abrogation of ligand expression was confirmed by RT-qPCR and activation of EGFR was assessed by immunoblotting. Despite effective knockdown of all three ligands (Figure 3c ) only cells lacking HB-EGF showed a significant reduction in the activation of EGFR in response to NPI-0052 (Figure 3d ). These data confirm that HB-EGF and not EGF or epiregulin is required for EGFR activation in response to proteasome inhibitor treatment. Knockdown of HB-EGF also sensitized BxPc3 cells to NPI-0052 treatment, shifting the Ic50 from 154 nM for Bx-Plko1 cells to 50 nM for Bx-shHB cells (data not shown).
We next sought to identify the signaling pathways involved in the induction of HB-EGF expression. Previous work by Ingram et al (2003) has shown that reactive oxygen species (ROS), ERK and p38-MAPK pathways are involved in HB-EGF expression in response to stress stimuli. Our study results show that inhibition of p38-MAPK (by SB203580) and ROS (by N-acetyl-cysteine, NAC) prevented NPI-0052-induced expression of HB-EGF and activation of EGFR, whereas inhibition of ERK (by PD98059) did not (Figure 4a ). p38-MAPK and ROS inhibition were also able to significantly reduce HB-EGF transcription (Figure 4b ). To ascertain if ROS was upstream of p38-MAPK activation, we treated BxPc3 cells with increasing concentrations of NAC (Figure 4c ). NPI-0052-induced p38-MAPK activity decreased in an NAC dosedependent manner, concomitantly with decreases in both HB-EGF and active EGFR levels. These results are in agreement with a previous study that highlighted the need for p38-MAPK and HB-EGF in the activation of EGFR in response to both osmotic and oxidative stresses (Fischer et al., 2004) .
We subsequently sought to identify the transcription factors downstream of the ROS/p38-MAPK pathway. Previous work has shown that p38-MAPK is able to phosphorylate and activate the transcription factor SP-1 (D' Addario et al., 2006) and that the HB-EGF promoter contains several SP-1-binding sites (Edwards et al., 2009) . To assess if SP-1 was involved in the induction of HB-EGF in response to NPI-0052, we transfected Panc1 cells with siRNA targeted against SP-1. At 48 h after transfection, SP-1 mRNA levels decreased to less than 7% of basal (Supplemental Figure 4) . Knockdown of SP-1 mRNA resulted in a significant decrease in both the mRNA and protein level of HB-EGF and a corresponding decrease in the NPI-0052-induced activation of EGFR (Figure 4d ). This suggests the transcription factor SP-1 is important in the induction of HB-EGF in response to proteasome inhibition.
Although we have shown here that HB-EGF is required for the activation of EGFR in tumor epithelial cells, it is also likely that increased HB-EGF expression and shedding in response to proteasome inhibitor treatment may additionally induce paracrine effects within the tumor microenvironment. This hypothesis is supported by recent work that has shown HB-EGF expression and EGFR signaling are responsible for pancreatic fibrosis (Means et al., 2003; Blaine et al., 2009) ; and that extracellular matrix deposition by the stroma can increase pancreatic cancer chemoresistance (Miyamoto et al., 2004) . HB-EGF and EGFR signaling in pancreatic tumor-stroma interactions may also explain the discordance between the limited efficacy of EGFR inhibitors in pancreatic cancer cell culture systems and the positive effects of EGFR inhibitors in murine models of pancreatic cancer and in the clinic (Buck et al., 2006; Moore et al., 2007; Sloss et al., 2008) . Moreover, as the dense stroma of pancreatic tumors has been implicated in the poor vascularization of tumors (Olive et al., 2009) . HB-EGF inhibition could potentially reduce stromal growth and increase drug penetration of pancreatic tumors. When the results shown here are viewed in this context, it is clear that HB-EGF targeting therapies will have multiple antipancreatic tumor effects: including reduced EGFR signaling in pancreatic cancer epithelial cells and reduced stromal growth and desmoplastic reaction. These combined effects should lead to a decrease in the growth and invasion of pancreatic tumors and an increase in chemosensitivity.
In summary, we have previously shown that proteasome inhibition can activate EGFR in pancreatic cancer cells and that inhibition of EGFR increases the efficacy of proteasome inhibitor treatment in a mouse xenograft model of pancreatic cancer (Sloss et al., 2008) . In this study we examined the role of EGFR ligands in the activation of EGFR in response to proteasome inhibition. Our study results indicate that proteasome inhibitor treatment induced the expression of EGF, epiregulin and HB-EGF but that only HB-EGF knockdown could abrogate EGFR activation. Activation of EGFR was also sensitive to both MMP/ADAM inhibition and ligand sequestration by an anti-HB-EGF antibody. These data indicate that HB-EGF expression and ligand cleavage are required for EGFR activation in response to proteasome inhibition. In addition, we found that induction of HB-EGF expression by NPI-0052 requires ROS, subsequent downstream p38-MAPK signaling and involves the transcription factor SP-1. Taking into consideration the significant antitumor potential of proteasome inhibition in pancreatic cancer models and the antiapoptotic effects of HB-EGF through both autocrine and paracrine mechanisms, we believe the combination of proteasome inhibitors and HB-EGF inhibitors warrant further investigation at both the preclinical and clinical levels. 
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